Filing Details
- Accession Number:
- 0001225208-18-015139
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-11-02 16:44:44
- Reporting Period:
- 2018-11-01
- Accepted Time:
- 2018-11-02 16:44:44
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 310158 | Merck & Co. Inc. | MRK | Pharmaceutical Preparations (2834) | 221918501 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1376841 | H Adam Schechter | Merck &Amp; Co., Inc. 2000 Galloping Hill Road Kenilworth NJ 07033 | Evp & Pres-Global Human Health | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2018-11-01 | 277,879 | $39.29 | 277,879 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2018-11-01 | 132,744 | $73.98 | 145,135 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-11-01 | 145,135 | $73.66 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2018-11-01 | 277,879 | $0.00 | 277,879 | $39.29 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2013-05-02 | 2022-05-01 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 55,406 | Indirect | By Trust |
Footnotes
- The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.6800 to $73.3900, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.4000 to $74.0200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
- Holdings include shares acquired in dividend reinvestment transactions.
- The option became exercisable in equal installments on 5/2/2013, 5/2/2014 and 5/2/2015.
Billionaire Hedge Funds
